Personal tools

Coexpression cluster:C255

From FANTOM5_SSTAR

Revision as of 15:18, 12 September 2012 by Autoedit (talk | contribs)
Jump to: navigation, search


Full id: C255_Wilms_leiomyoblastoma_kidney_adrenal_MCF7_epithelioid_Mast



Phase1 CAGE Peaks

Hg19::chr10:43867077..43867098,+p1@FXYD4
Hg19::chr10:84983078..84983087,+p@chr10:84983078..84983087
+
Hg19::chr11:121513919..121513924,-p@chr11:121513919..121513924
-
Hg19::chr11:77792240..77792241,+p@chr11:77792240..77792241
+
Hg19::chr11:77792301..77792328,+p@chr11:77792301..77792328
+
Hg19::chr12:42983782..42983815,-p2@PRICKLE1
Hg19::chr12:42983843..42983865,-p3@PRICKLE1
Hg19::chr12:43946001..43946016,-p1@ADAMTS20
Hg19::chr15:39561378..39561415,-p@chr15:39561378..39561415
-
Hg19::chr15:88119982..88120003,+p2@LINC00052
Hg19::chr15:88120158..88120161,+p1@LINC00052
Hg19::chr15:88799370..88799383,-p6@NTRK3
Hg19::chr16:80838418..80838432,-p5@CDYL2
Hg19::chr16:80838441..80838473,-p2@CDYL2
Hg19::chr16:80838479..80838508,-p1@CDYL2
Hg19::chr17:41132410..41132418,-p8@AARSD1
Hg19::chr19:46651474..46651514,+p1@IGFL2
Hg19::chr19:50381565..50381605,-p4@AKT1S1
Hg19::chr1:153517273..153517295,-p5@S100A4
Hg19::chr1:172347750..172347761,+p11@DNM3
Hg19::chr1:180601188..180601207,+p2@XPR1
Hg19::chr1:180601215..180601233,+p4@XPR1
Hg19::chr1:183387723..183387763,-p7@NMNAT2
Hg19::chr1:201438498..201438583,-p3@PHLDA3
Hg19::chr1:201532249..201532262,+p@chr1:201532249..201532262
+
Hg19::chr1:201532269..201532289,+p@chr1:201532269..201532289
+
Hg19::chr1:43387667..43387671,-p@chr1:43387667..43387671
-
Hg19::chr1:62785019..62785032,-p4@KANK4
Hg19::chr1:62902308..62902335,+p9@USP1
Hg19::chr1:62902336..62902387,+p2@USP1
Hg19::chr1:62902414..62902438,+p5@USP1
Hg19::chr1:63213403..63213406,+p@chr1:63213403..63213406
+
Hg19::chr1:69521584..69521593,+p2@ENST00000425517
Hg19::chr20:42545244..42545247,-p@chr20:42545244..42545247
-
Hg19::chr21:18218138..18218142,-p@chr21:18218138..18218142
-
Hg19::chr2:139791638..139791647,+p@chr2:139791638..139791647
+
Hg19::chr2:140592929..140592932,+p@chr2:140592929..140592932
+
Hg19::chr3:47088671..47088676,-p28@SETD2
Hg19::chr3:96532316..96532327,+p@chr3:96532316..96532327
+
Hg19::chr3:96533452..96533467,+p3@EPHA6
Hg19::chr5:103006456..103006466,+p@chr5:103006456..103006466
+
Hg19::chr5:103012042..103012047,+p@chr5:103012042..103012047
+
Hg19::chr5:159343481..159343528,+p1@ADRA1B
Hg19::chr5:159343688..159343754,+p2@ADRA1B
Hg19::chr5:159343995..159344006,+p5@ADRA1B
Hg19::chr5:56247250..56247252,-p@chr5:56247250..56247252
-
Hg19::chr5:56248032..56248039,-p3@MIER3
Hg19::chr7:116070621..116070623,-p@chr7:116070621..116070623
-
Hg19::chr7:139168434..139168465,-p2@KLRG2
Hg19::chr9:15552504..15552550,+p13@C9orf93
Hg19::chrX:13062697..13062745,-p1@FAM9C


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data

No results for this coexpression

Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data

GO IDGO nameFDR corrected p-value
GO:0031330negative regulation of cellular catabolic process0.0243337650614231
GO:0045818negative regulation of glycogen catabolic process0.0243337650614231
GO:0045819positive regulation of glycogen catabolic process0.0243337650614231
GO:0031329regulation of cellular catabolic process0.0243337650614231
GO:0005981regulation of glycogen catabolic process0.0243337650614231
GO:0001987vasoconstriction of artery involved in baroreceptor response to lowering of systemic arterial blood pressure0.0243337650614231
GO:0043278response to morphine0.0243337650614231
GO:0031331positive regulation of cellular catabolic process0.0243337650614231
GO:0014072response to isoquinoline alkaloid0.0243337650614231
GO:0001982baroreceptor response to decreased systemic arterial blood pressure0.0291923521403618
GO:0003099positive regulation of the force of heart contraction by chemical signal0.0291923521403618
GO:0001996positive regulation of heart rate by epinephrine-norepinephrine0.0291923521403618
GO:0048148behavioral response to cocaine0.0291923521403618
GO:0003057regulation of the force of heart contraction by chemical signal0.0291923521403618
GO:0001997positive regulation of the force of heart contraction by epinephrine-norepinephrine0.0291923521403618
GO:0004813alanine-tRNA ligase activity0.0298474661164654
GO:0045912negative regulation of carbohydrate metabolic process0.0298474661164654
GO:0010460positive regulation of heart rate0.0298474661164654
GO:0006419alanyl-tRNA aminoacylation0.0298474661164654
GO:0000309nicotinamide-nucleotide adenylyltransferase activity0.0298474661164654
GO:0042220response to cocaine0.0298474661164654
GO:0014073response to tropane0.0298474661164654
GO:0004714transmembrane receptor protein tyrosine kinase activity0.030184957028829
GO:0001978carotid sinus baroreceptor feedback regulation of systemic arterial blood pressure0.0312600309926838
GO:0003025baroreceptor regulation of systemic arterial blood pressure0.0312600309926838
GO:0001975response to amphetamine0.0312600309926838
GO:0014075response to amine stimulus0.0312600309926838
GO:0043526neuroprotection0.0312600309926838
GO:0019199transmembrane receptor protein kinase activity0.0321704466659882
GO:0004937alpha1-adrenergic receptor activity0.0321704466659882
GO:0043121neurotrophin binding0.0321704466659882
GO:0035265organ growth0.0321704466659882
GO:0045823positive regulation of heart contraction0.0321704466659882
GO:0001993regulation of systemic arterial blood pressure by norepinephrine-epinephrine0.0321704466659882
GO:0002027regulation of heart rate0.0347831181905141
GO:0005980glycogen catabolic process0.0347831181905141
GO:0009251glucan catabolic process0.0347831181905141
GO:0045913positive regulation of carbohydrate metabolic process0.0347831181905141
GO:0007512adult heart development0.0347831181905141
GO:0002026regulation of the force of heart contraction0.0347831181905141
GO:0009896positive regulation of catabolic process0.0347831181905141
GO:0001974blood vessel remodeling0.0347831181905141
GO:0003084positive regulation of systemic arterial blood pressure0.0347831181905141
GO:0008542visual learning0.0347831181905141
GO:0001976regulation of systemic arterial blood pressure by neurological process0.0364292713497891
GO:0006109regulation of carbohydrate metabolic process0.0364292713497891
GO:0000299integral to membrane of membrane fraction0.0364292713497891
GO:0043279response to alkaloid0.0364292713497891
GO:0009895negative regulation of catabolic process0.0393326162769219
GO:0004936alpha-adrenergic receptor activity0.0393326162769219
GO:0007632visual behavior0.0420102813890101
GO:0045777positive regulation of blood pressure0.0420102813890101
GO:0014070response to organic cyclic substance0.0444873434181894
GO:0001837epithelial to mesenchymal transition0.0444873434181894
GO:0007169transmembrane receptor protein tyrosine kinase signaling pathway0.0454180426281821
GO:0003044regulation of systemic arterial blood pressure mediated by a chemical signal0.0467852967057092



Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br><br>uberon_data<br>disease_data<br>

Uber Anatomy
Ontology termp-valuen
central nervous system2.06e-2582
regional part of nervous system3.38e-2494
nervous system3.38e-2494
neural tube1.09e-2357
neural rod1.09e-2357
future spinal cord1.09e-2357
neural keel1.09e-2357
brain6.64e-2269
future brain6.64e-2269
regional part of brain5.57e-2059
ectoderm-derived structure4.74e-19169
multi-cellular organism5.38e-19659
neural plate7.70e-1986
presumptive neural plate7.70e-1986
anterior neural tube1.47e-1842
regional part of forebrain3.75e-1841
forebrain3.75e-1841
future forebrain3.75e-1841
ectoderm1.42e-17173
presumptive ectoderm1.42e-17173
gray matter2.30e-1734
brain grey matter2.30e-1734
telencephalon6.32e-1734
neurectoderm1.17e-1690
cerebral hemisphere2.11e-1632
regional part of telencephalon2.47e-1633
anatomical system4.74e-16625
anatomical group1.15e-15626
organ1.23e-15511
adult organism1.31e-15115
organ part4.69e-15219
cerebral cortex5.16e-1425
pallium5.16e-1425
head1.87e-13123
pre-chordal neural plate7.88e-1361
regional part of cerebral cortex8.80e-1322
anterior region of body1.05e-12129
craniocervical region1.05e-12129
embryo1.88e-12612
neocortex3.26e-1220
anatomical cluster4.82e-11286
embryonic structure8.73e-11605
developing anatomical structure8.73e-11605
tube1.59e-10194
germ layer1.85e-10604
embryonic tissue1.85e-10604
presumptive structure1.85e-10604
epiblast (generic)1.85e-10604
anatomical conduit1.77e-09241
organism subdivision1.24e-08365
Disease
Ontology termp-valuen
cell type cancer6.05e-09143
carcinoma2.47e-08106


Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data

Novel motifs



JASPAR motifs

Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}



ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data

(#promoters = Number of promoters in this coexpression cluster that have ChIP signal of the TF)

TF#promotersEnrichmentp-valueq-value
CTCF#10664171.786752124358340.009002194809137830.0341300404280519



Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data

Retrieved from "http://f5-webapp4.gsc.riken.jp/resource_browser/index.php?title=Coexpression_cluster:C255&oldid=2137251"